Arbutus Biopharma Files 2024 10-K
Ticker: ABUS · Form: 10-K · Filed: 2025-03-27T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, pharmaceuticals, financials
TL;DR
Arbutus Biopharma filed its 2024 10-K. Check financials.
AI Summary
Arbutus Biopharma Corp filed its 2024 10-K on March 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Tekmira Pharmaceuticals Corp, is involved in the pharmaceutical preparations industry. The filing covers various financial and operational aspects of the company, including its business address in Warminster, PA, and its former name changes.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Arbutus Biopharma's financial health and business operations for the fiscal year 2024, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Arbutus Biopharma faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
- 001-34949 — SEC File Number (Company's SEC filing identifier)
Key Players & Entities
- Arbutus Biopharma Corp (company) — Filer of the 10-K
- Tekmira Pharmaceuticals Corp (company) — Former name of Arbutus Biopharma Corp
- Warminster, PA (location) — Business and mailing address
- 2024-12-31 (date) — Fiscal year end
- 2025-03-27 (date) — Filing date
FAQ
What is Arbutus Biopharma Corp's primary business activity?
Arbutus Biopharma Corp is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code 2834.
When did Arbutus Biopharma Corp file its 10-K report?
Arbutus Biopharma Corp filed its 10-K report on March 27, 2025.
What fiscal year does this 10-K report cover?
This 10-K report covers the fiscal year ending December 31, 2024.
What was Arbutus Biopharma Corp formerly known as?
Arbutus Biopharma Corp was formerly known as TEKMIRA PHARMACEUTICALS Corp.
Where is Arbutus Biopharma Corp's business located?
Arbutus Biopharma Corp's business address is 701 Veterans Circle, Warminster, PA 18974.
From the Filing
0001447028-25-000083.txt : 20250327 0001447028-25-000083.hdr.sgml : 20250327 20250327073142 ACCESSION NUMBER: 0001447028-25-000083 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 107 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250327 DATE AS OF CHANGE: 20250327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 25775311 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 10-K 1 abus-20241231.htm 10-K abus-20241231 false 0001447028 2024 FY iso4217:USD iso4217:USD xbrli:shares xbrli:shares abus:subsidiary xbrli:pure abus:numberOfSegments abus:lease abus:renewal_option utr:Rate abus:product abus:employee 0001447028 2024-01-01 2024-12-31 0001447028 2024-06-30 0001447028 2025-03-25 0001447028 abus:OMERSMember 2019-07-02 2022-12-31 0001447028 2024-12-31 0001447028 2023-12-31 0001447028 abus:CollaborationAndContractsMember 2024-01-01 2024-12-31 0001447028 abus:CollaborationAndContractsMember 2023-01-01 2023-12-31 0001447028 abus:NonCashRoyaltyMember 2024-01-01 2024-12-31 0001447028 abus:NonCashRoyaltyMember 2023-01-01 2023-12-31 0001447028 2023-01-01 2023-12-31 0001447028 us-gaap:CommonStockMember 2022-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001447028 us-gaap:RetainedEarningsMember 2022-12-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001447028 2022-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001447028 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001447028 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001447028 us-gaap:CommonStockMember 2023-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001447028 us-gaap:RetainedEarningsMember 2023-12-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001447028 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001447028 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001447028 us-gaap:CommonStockMember 2024-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001447028 us-gaap:RetainedEarningsMember 2024-12-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001447028 abus:GenevantSciencesCorporationMember 2024-12-31 0001447028 abus:LaboratoryEquipmentMember 2024-12-31 0001447028 srt:MinimumMember us-gaap:ComputerEquipmentMember 2024-12-31 0001447028 srt:MaximumMember us-gaap:ComputerEquipmentMember 2024-12-31 0001447028 us-gaap:FurnitureAndFixturesMember 2024-12-31 0001447028 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001447028 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-01-01 2024-12-31 0001447028 us-gaap:EmployeeStockOptionMember abus:DirectorsAndExecutivesMember 2024-01-01 2024-12-31 0001447028 abus:EnantigenTherapeuticsIncMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0001447028 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember srt:MinimumMember 2024-12-31 0001447028 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember srt:MaximumMember 2024-12-31 0001447028 us-gaap:FairValueInputsLevel3Member abus:P